TMB High
Tumor Mutational Burden ≥10 mut/Mb. Indication for pembrolizumab across solid tumors.
No Clinical Trials found for this biomarker.
Tumor Mutational Burden ≥10 mut/Mb. Indication for pembrolizumab across solid tumors.
No Clinical Trials found for this biomarker.